Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT9402-27-Q-9101
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Department of Defense, through the Defense Health Agency (DHA), has issued a solicitation (Procurement Identifier: HT9402-27-Q-9101) seeking quotations for pharmaceutical agents as part of its ongoing efforts to maintain and enhance the Military Health System’s (MHS) integrated pharmacy benefits program. This procurement is mandated by 10 U.S.C. § 1074g and its implementing regulation (32 CFR Section 199.21), which require the establishment of an effective and efficient pharmacy program for military beneficiaries. The program’s core objective is to ensure access to clinically effective and cost-efficient pharmaceutical agents, as determined by the Department of War (DoW) Pharmacy and Therapeutics (P&T) Committee.
The scope of this solicitation encompasses the acquisition of pharmaceutical agents within specific drug classes identified for review and potential placement on the DoW Uniform Formulary (UF). The UF is a standardized list of medications available to MHS beneficiaries, and agents are classified for cost-sharing purposes as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). The P&T Committee evaluates both the clinical and cost effectiveness of agents within each therapeutic class before making recommendations for formulary placement.
For the February 2027 P&T Committee meeting, the following drug classes and specific agents are under review:
a. Ophthalmic – Dry Eye:
- Cequa
- Eysuvis
- Miebo
- Tryptyr
- Tyrvaya
- Verkazia
- Vevye
- Xiidra
b. Testosterone Replacement Therapy – Orals:
- Jatenzo
- Kyzatrex
- Tlando
The DHA will consider awarding Uniform Formulary Blanket Purchase Agreements (UF BPAs) and Uniform Formulary Additional Discount Program Agreements (UF ADPs) based on the outcomes of the P&T Committee’s review. The attached Request for Quotation (RFQ) and its appendices provide detailed instructions, requirements, and deadlines for submission. Notably, a pre-quotation teleconference is scheduled for November 17, 2026, with further details available in Part 2.4 of the RFQ.
Key requirements for this procurement include the provision of competitive pricing for the specified pharmaceutical agents, compliance with all regulatory and programmatic guidelines, and the ability to support the MHS’s large and diverse beneficiary population. Contractors must be capable of manufacturing and supplying pharmaceutical preparations in accordance with NAICS Code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505.
The place of performance for this contract is San Antonio, Texas, United States. The contracting activity is managed by the Defense Health Agency, a federal office under the Department of Defense. Interested parties should direct inquiries to the primary contact, Stephanie Erpelding ([email protected]), or the secondary contact, Julianne Canaley ([email protected]).
This opportunity is currently active, with a response deadline of July 12, 2026. All relevant solicitation documents, including the RFQ and appendices, are available via the official SAM.gov posting (Opportunity ID: 4379b35024844e9e8afaa128b80b3809).
Contractors with expertise in pharmaceutical manufacturing and distribution, particularly those with experience in federal healthcare programs and formulary management, are encouraged to review the solicitation in detail to determine alignment with their capabilities and strategic objectives. This procurement represents a significant opportunity to support the health and readiness of the military community through the provision of high-quality, cost-effective pharmaceutical agents.
Documents6